Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paritaprevir + ritonavir + pibrentasvir + ribavirin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Paritaprevir + ritonavir + pibrentasvir + ribavirin** is an unverified four-agent oral hepatitis C antiviral co-administration regimen rather than a confirmed marketed fixed-dose product. Paritaprevir inhibits the hepatitis C virus NS3/4A protease, ritonavir inhibits CYP3A-mediated paritaprevir metabolism to boost paritaprevir exposure, pibrentasvir inhibits hepatitis C virus NS5A, and ribavirin is a synthetic nucleoside analogue with incompletely established anti-HCV activity. Public regulatory sources instead document paritaprevir/ritonavir in products containing ombitasvir, and pibrentasvir in the glecaprevir/pibrentasvir product Mavyret. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206619s010lbl.pdf))
- Other names
- paritaprevir + ritonavir + pibrentasvir + ribavirin
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)ABCG2 (Breast cancer resistance protein)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))CYP3A4 (Cytochrome P450 3A4)SLCO1B3 (Organic anion transporting polypeptide 1B3)ABCB1 (P-glycoprotein)NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on paritaprevir + ritonavir + pibrentasvir + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paritaprevir + ritonavir + pibrentasvir + ribavirin.